title: Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer.
abstract: To elaborate a rational approach to chemoimmunotherapy in humans, information is required as to how current cytotoxic chemotherapy regimens modulate patients' endogenous immune cells. We have studied a group of 16 advanced breast cancer patients who received cyclical cytotoxic chemotherapy (CMF-cyclophosphamide, methotrexate and 5-fluorouracil) and have documented the progressive differential effects of chemotherapy on endogenous immune cells as judged by changes in immunophenotype and absolute numbers of lymphocyte subsets, together with analysis of natural-killer-cell function. Cells with the immunophenotype of natural killer cells and lymphokine-activated killer cells (NK/LAK cells) were well retained, but their function was suboptimal. Additionally, CD8 T cells were well preserved, but the numbers of CD4 T cells decreased with succeeding cycles of chemotherapy; B-cell numbers decreased rapidly from the first cycle of chemotherapy. These cellular changes in humans indicate defined and precisely timed windows of opportunity for introducing in vivo, simple and direct immune stimulation of the cells modulated by chemotherapy, with the possibility of improving therapy and survival in this disease.
authors.affiliation: Department of Immunology, University Hospital, Queens Medical Centre, Nottingham, UK.
authors.forename: H F
authors.initials: HF
authors.lastname: Sewell
authors.forename: C F
authors.initials: CF
authors.lastname: Halbert
authors.forename: R A
authors.initials: RA
authors.lastname: Robins
authors.forename: A
authors.initials: A
authors.lastname: Galvin
authors.forename: S
authors.initials: S
authors.lastname: Chan
authors.forename: R W
authors.initials: RW
authors.lastname: Blamey
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001402:B-Lymphocytes / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D002945:Cisplatin / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D016130:Immunophenotyping; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000473:pathology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000473:pathology; D007958:Leukocyte Count; D016131:Lymphocyte Subsets / Q000473:pathology*; D008727:Methotrexate / Q000009:adverse effects
chemical_list: D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate